{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:31:18Z","timestamp":1780669878215,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heinrich-Lohst\u00f6ter-Stiftung"},{"DOI":"10.13039\/501100000781","name":"European Research Council (NanoImmune)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.03.057","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T09:53:53Z","timestamp":1458813233000},"page":"2453-2459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses"],"prefix":"10.1016","volume":"34","author":[{"given":"Ziad","family":"Julier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"de Titta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliz\u00e9e J.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Simeoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody A.","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Hubbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2016.03.057_bib0120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.coph.2011.03.004","article-title":"TLR based therapeutics","volume":"11","author":"Dunne","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.03.057_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/nat.2012.0340","article-title":"CpG still rocks! Update on an accidental drug","volume":"22","author":"Krieg","year":"2012","journal-title":"Nucleic Acid Ther"},{"issue":"December (49)","key":"10.1016\/j.vaccine.2016.03.057_bib0130","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose","volume":"110","author":"de Titta","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2016.03.057_bib0135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"10.1016\/j.vaccine.2016.03.057_bib0140","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1074\/jbc.M100099200","article-title":"The extra domain A of fibronectin activates Toll-like receptor 4","volume":"276","author":"Okamura","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.03.057_bib0145","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1038\/srep08569","article-title":"The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine","volume":"5","author":"Julier","year":"2015","journal-title":"Sci Rep"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2016.03.057_bib0150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.4049\/jimmunol.178.2.748","article-title":"The extra domain a from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo","volume":"178","author":"Lasarte","year":"2007","journal-title":"J Immunol"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2016.03.057_bib0155","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2009.06.005","article-title":"Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein","volume":"51","author":"Mansilla","year":"2009","journal-title":"J Hepatol"},{"issue":"42","key":"10.1016\/j.vaccine.2016.03.057_bib0160","doi-asserted-by":"crossref","first-page":"16260","DOI":"10.1073\/pnas.0805325105","article-title":"Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines","volume":"105","author":"Zhu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2016.03.057_bib0165","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4049\/jimmunol.178.2.1164","article-title":"MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists","volume":"178","author":"Bagchi","year":"2007","journal-title":"J Immunol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2016.03.057_bib0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni1223","article-title":"Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells","volume":"6","author":"Napolitani","year":"2005","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.03.057_bib0175","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1039\/c3ib20263a","article-title":"A high-throughput nanoimmunoassay chip applied to large-scale vaccine adjuvant screening","volume":"5","author":"Garcia-Cordero","year":"2013","journal-title":"Integr Biol (Camb)"},{"issue":"2","key":"10.1016\/j.vaccine.2016.03.057_bib0180","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI39293","article-title":"Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice","volume":"120","author":"Zhu","year":"2010","journal-title":"J Clin Invest"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2016.03.057_bib0185","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1128\/JVI.69.10.6158-6169.1995","article-title":"High-level hepatitis B virus replication in transgenic mice","volume":"69","author":"Guidotti","year":"1995","journal-title":"J Virol"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2016.03.057_bib0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00430-014-0378-6","article-title":"Mouse models for therapeutic vaccination against hepatitis B virus","volume":"204","author":"Dembek","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2016.03.057_bib0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2016.03.057_bib0200","doi-asserted-by":"crossref","first-page":"329405","DOI":"10.1155\/2015\/329405","article-title":"Effect of TLR4\/MyD88 signaling pathway on expression of IL-1\u03b2 and TNF-\u03b1 in synovial fibroblasts from temporomandibular joint exposed to lipopolysaccharide","volume":"2015","author":"Lin","year":"2015","journal-title":"Mediat Inflamm"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2016.03.057_bib0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nmat2357","article-title":"Infection-mimicking materials to program dendritic cells in situ","volume":"8","author":"Ali","year":"2009","journal-title":"Nat Mater"},{"issue":"4","key":"10.1016\/j.vaccine.2016.03.057_bib0210","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1021\/mp900038e","article-title":"In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines","volume":"6","author":"Beaudette","year":"2010","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.vaccine.2016.03.057_bib0215","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.vaccine.2012.12.074","article-title":"A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice","volume":"31","author":"Buchmann","year":"2013","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2016.03.057_bib0220","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-14-0019-T","article-title":"Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes","volume":"2","author":"Jeanbart","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"April","key":"10.1016\/j.vaccine.2016.03.057_bib0225","doi-asserted-by":"crossref","first-page":"14274","DOI":"10.1038\/srep14274","article-title":"Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice","volume":"5","author":"Ballester","year":"2015","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2016.03.057_bib0230","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2174\/138161209787846793","article-title":"Clinical experience with therapeutic vaccines designed for patients with hepatitis","volume":"15","author":"Batdelger","year":"2009","journal-title":"Curr Pharm Des"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16300408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T23:14:42Z","timestamp":1748819682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16300408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16300408"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}